CHAPTER 1. INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2. RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3. MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4. MARKET DYNAMICS
4.1. Market Drivers
4.1.1. The rise in venture capital investments
4.1.2. Increase in government investments and R&D
4.1.3. Growing use of synthesised oligonucleotides in molecular diagnostic’s
4.2. Market Restraints & Challenges
4.2.1. Large-scale synthesis of oligonucleotides
4.2.2. Price erosion of synthesised oligonucleotides
4.3. Market Opportunities
4.3.1. Emerging economies
CHAPTER 5. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET – BY
PRODUCT
5.1. Introduction
5.2. Synthesized Oligonucleotides
5.2.1. By Type
5.2.2.1. Custom Oligonucleotides
5.2.2.2. Pre-Designed Oligonucleotides
5.2.2. By Product
5.2.1.1. Primers
5.2.1.2. Probes
5.2.1.3. Large-Scale Synthesis Oligonucleotides
5.2.1.4. Intermediate-Scale Synthesis Oligonucleotides
5.2.1.5. Linkers & Adaptors
5.3. Reagents
5.4. Equipment
CHAPTER 6. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET – BY
APPLICATION
6.1. Introduction
6.2. Diagnostics
6.3. Therapeutics
6.3.1. RNAi
6.3.2. Nucleic Acid Aptamers
6.3.3. DNA/Antisense Oligonucleotides
6.3.4. Immunotherapy Applications
6.4. Research
6.4.1. PCR
6.4.2. QPCR
6.4.3. Sequencing
6.4.4. Gene Synthesis
6.4.5. Other Research Applications
CHAPTER 7. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET – BY END
USER
7.1. Introduction
7.2. Diagnostic Laboratories
7.3. Pharmaceutical and Biotechnology Companies
7.4. Academic Research Institutes
7.5. Other End Users
CHAPTER 8. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET - BY
GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. U.S.
8.2.2. Canada
8.2.3. Mexico
8.2.4. Costa Rica
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Chile
8.3.4. Columbia
8.3.5. Others
8.4. Europe
8.4.1. U.K.
8.4.2. Germany
8.4.3. France
8.4.4. Italy
8.4.5. Spain
8.4.6. Russia
8.4.7. Netherlands
8.4.8. Switzerland
8.4.9. Poland
8.4.10. Others
8.5. APAC
8.5.1. China
8.5.2. Japan
8.5.3. India
8.5.4. South Korea
8.5.5. Australia & New Zealand
8.5.6. Malaysia
8.5.7. Singapore
8.5.8. Others
8.6. Middle East & Africa
8.6.1. UAE
8.6.2. Saudi Arabia
8.6.3. Iran
8.6.4. Iraq
8.6.5. Qatar
8.6.6. South Africa
8.6.7. Algeria
8.6.8. Morocco
8.6.9. Nigeria
8.6.10. Egypt
8.6.11. Others
CHAPTER 9. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET - COMPANY
PROFILES
9.1. Integrated DNA Technologies
9.2. Merck KGaA
9.3. Eurofins Genomics
9.4. Thermo Fisher Scientific
9.5. Bioautomation Corporation
9.6. Agilent Technologies
9.7. Eurogentec
9.8. GE Healthcare
9.9. LGC Biosearch Technologies
9.10. Nitto Denko Avecia Inc
9.11. Genscript Corporation
9.12. Genedesign (Part of Ajinomoto)
9.13. TriLink Biotechnologies, Inc
9.14. Bio-Synthesis
9.15. ATDBio Ltd
CHAPTER 10. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET -
COMPETITIVE LANDSCAPE
10.1. Market Share Analysis
10.2. Strategies adopted by top companies
10.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 11. MARKET INSIGHTS
11.1. Industry Experts Insights
11.2. Analysts Opinions
11.3. Investment Opportunities
CHAPTER 12. APPENDIX
12.1. List of Tables
12.2. List of Figures